Encorafenib

Major

Encorafenib Disopyramide Norpace Increased risk of QT interval prolongation Details Encorafenib Dofetilide Tikosyn Increased risk of QT interval prolongation Details Encorafenib Dolasetron Anzemet Increased risk of QT interval prolongation Details Encorafenib Dolasetron Injection Anzemet Increased risk of QT interval prolongation Details Encorafenib Elacestrant Orserdu Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Adagrasib Krazati An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Encorafenib Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Encorafenib Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Encorafenib Alfentanil Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Amiodarone Nexterone Increased risk of QT interval prolongation Details Encorafenib Amisulpride Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Encorafenib Amprenavir Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Apalutamide Erleada Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Apomorphine Apokyn Increased risk of QT interval prolongation Details Encorafenib Aprepitant Aponvie Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions, reduced sensitive CYP3A4 substrate exp... Details Encorafenib Aripiprazole Abilify Reduced ARIPiprazole or ARIPiprazole lauroxil (prodrug of ARIPiprazole) exposure and an increased risk of QT interval prolongation Details Encorafenib Aripiprazole Lauroxil Aristada Reduced ARIPiprazole or ARIPiprazole lauroxil (prodrug of ARIPiprazole) exposure and an increased risk of QT interval prolongation Details Encorafenib Artemether Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine, loss of antimalarial efficacy, reduced CYP3... Details Encorafenib Asenapine Saphris Increased risk of QT interval prolongation Details Encorafenib Astemizole Increased risk of QT interval prolongation Details Encorafenib Atrasentan Altered atrasentan exposure, reduced efficacy of atrasentan and an increased risk of atrasentan-related adverse reaction Details Encorafenib Avacopan Tavneos Increased CYP3A4 substrate exposure Details Encorafenib Berotralstat Orladeyo Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Boceprevir Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Bosentan Reduced encorafenib exposure, reduced efficacy of encorafenib, increased bosentan exposure and increased risk of bosentan-related... Details Encorafenib Buspirone Bucapsol Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Cannabidiol Epidiolex Reduced exposure of cannabidiol and reduced active cannabidiol metabolite exposure Details Encorafenib Carbamazepine Carbatrol Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Cenobamate Xcopri Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Ceritinib Zykadia Increased encorafenib exposure, an increased risk of encorafenib-related adverse reaction and an increased risk of QT interval pro... Details Encorafenib Chlorpromazine Increased risk of QT interval prolongation Details Encorafenib Cholera Vaccine Ipol An increased risk of infection by the live vaccine Details Encorafenib Ciprofloxacin Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Encorafenib Citalopram Celexa Increased risk of QT interval prolongation Details Encorafenib Clarithromycin Biaxin Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Encorafenib Clofazimine Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Encorafenib Clomipramine Anafranil Increased risk of QT interval prolongation Details Encorafenib Clothiapine Increased risk of cardiac arrhythmias Details Encorafenib Clozapine Clozaril Increased risk of QT interval prolongation Details Encorafenib Cobicistat Tybost Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details